65,437 trials
Obesity · Type 2 Diabetes
Primary: Percent Weight Loss From Baseline to Week 56 — 1.24; 7.81; 9.84 percent weight loss — p=<0.0001
Cocaine Dependence · Substance-induced Sleep Disorder · Substance-induced Cognitive Disorder
Primary: Total Sleep Time (Minutes) — 364; 379 Minutes
Allergic Rhinitis (AR)
Primary: Initial Deposition of Radioactivity Within the Nasal Cavity as a Percent of Delivered Dose — 99.48; 86.28 percentage of radiolabeled
Endometrial Cancer
Primary: Overall Disease Control Rate — 17 percentage of participants
Obesity
Primary: Percent Weight Loss From Baseline to Week 56 — 1.55; 5.10; 10.92 percent weight loss — p=<0.0001
Diabetic Macular Edema
Primary: Number of Study Eyes Demonstrating an Increase or Decrease in Best-corrected Visual Acuity (BCVA) of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS)…
Colorectal Cancer
Primary: Disease-free Survival in Stage III Cancer Patients - Time to Event — NA; NA; NA months — p=0.2024
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Number of Participants With Radiographic Objective Response (OR) — 0 participants
Focal Dystonia
Primary: Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline — 3.71; 3.03 month
Stomach Cancer
Primary: Relapse-free Survival — 50.0; 60.2 percentage of participants
Breast Cancer · Depression · Fatigue
Primary: Fatigue Using the Brief Fatigue Inventory (BFI) — 2.786; 1.356 units on a scale
Pneumococcal Infections
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1 — 146; 104; 200; 353 titer
Lymphoma, Large-Cell, Diffuse
Primary: Number of Participants With Overall Response (OR), as Assessed by the Investigator — 18; 18; 36 participants
Healthy
Primary: Discomfort — 2.25; 2.52 units on a scale
Breast Cancer
Primary: Number of Participants Experiencing in Situ Anti-tumor Effect of Tarceva — 8 participants